Application of sofosbuvir in HCV-infected patients with end-stage renal disease undergoing hemodialysis

Zujiang YU; Ye ZHANG; Jianqi LIAN

doi:10.3969/j.issn.1001-5256.2021.05.045

Volume 37 Issue 5

May 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(5): 1193-1196

PDF( 1884 KB)

Application of sofosbuvir in HCV-infected patients with end-stage renal disease undergoing hemodialysis

DOI: 10.3969/j.issn.1001-5256.2021.05.045

1.
Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
2.
Department of Infectious Diseases, The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China

Received Date: 2020-09-30
Accepted Date: 2020-10-30
Published Date: 2021-05-20

Abstract

Abstract

For chronic hepatitis C patents with end-stage renal disease (ESRD) undergoing hemodialysis, most guidelines recommend the use of direct-acting antivirals containing protease inhibitor (PI), yet dialysis patients with severe liver injury are often unable to receive such treatment due to contraindications to PIs. This article briefly introduces the unmet treatment needs in hepatitis C patients with ESRD undergoing dialysis, reviews the data from clinical trials and real-world studies investigating the use of PI-free sofosbuvir (SOF)-based regimens in such patients, and explores the value of SOF-based regimens in the treatment of dialysis patients in China and issues requiring further research. It is pointed out that full-dose SOF-based regimens have good clinical effect, tolerability, and safety in dialysis patients and thus provide additional safe and effective treatment options for such patients with moderate or severe liver injury.
- Hepatitis C,
- Antiviral Agents,
- Nephrosis,
- Renal Dialysis,
- Kidney Failure, Chronic

FullText(HTML)

References(42)

References

[1]	CORSON M, MOCH A, SAAB S. Hepatitis C virus treatment in patients with chronic kidney disease and in kidney transplant recipients[J]. Gastroenterol Hepatol (N Y), 2018, 14(5): 280-285.
[2]	Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl (2011), 2018, 8(3): 91-165. DOI: 10.1016/j.kisu.2018.06.001.
[3]	AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection[J]. Clin Infect Dis, 2018, 67(10): 1477-1492. DOI: 10.1093/cid/ciy585.
[4]	European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2): 461-511. DOI: 10.1016/j.jhep.2018.03.026.
[5]	MEHTA R, DESAI K, KABRAWALA M, et al. Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis[J]. Indian J Gastroenterol, 2018, 37(1): 72-73. DOI: 10.1007/s12664-018-0833-1.
[6]	WANG F, YANG C, LONG JY, et al. Executive summary for the 2015 annual data report of the China Kidney Disease Network (CK-NET)[J]. Kidney Int, 2019, 95(3): 501-505. DOI: 10.1016/J.kint.2018.11.011.
[7]	LI M, CHEN J, FANG Z, et al. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: A systematic review and meta-analysis[J]. Virol J, 2019, 16(1): 34. DOI: 10.1186/s12985-019-1140-x.
[8]	GAO Y, YANG J, SUN F, et al. Prevalence of anti-HCV antibody among the general population in Mainland China between 1991 and 2015: A systematic review and meta-analysis[J]. Open Forum Infect Dis, 2019, 6(3): ofz040. DOI: 10.1093/ofid/ofz040.
[9]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[10]	PARK H, CHEN C, WANG W, et al. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD[J]. Hepatology, 2018, 67(2): 492-504. DOI: 10.1002/hep.29505.
[11]	MOLNAR MZ, ALHOURANI HM, WALL BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans[J]. Hepatology, 2015, 61(5): 1495-1502. DOI: 10.1002/hep.27664.
[12]	FABRIZI F, DIXIT V, MESSA P. Impact of hepatitis C on survival in dialysis patients: A link with cardiovascular mortality?[J]. J Viral Hepat, 2012, 19(9): 601-607. DOI: 10.1111/j.1365-2893.2012.01633.x.
[13]	The committee of expert consensus for the diagnosis and treatment of chronic kidney disease with hepatitis C infection. The expert consensus for the diagnosis and treatment of chronic kidney disease with hepatitis C infection[J]. J Clin Nephrol, 2019, 19(5): 305-310. DOI: 10.3969/j.issn.1671-2390.2019.05.001. CKD合并HCV感染诊治共识专家委员会. 慢性肾脏病合并丙型肝炎病毒感染诊断及治疗的专家共识[J]. 临床肾脏病杂志, 2019, 19(5): 305-310. DOI: 10.3969/j.issn.1671-2390.2019.05.001.
[14]	MAK LY, SETO WK, LAI CL, et al. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection[J]. Expert Opin Drug Metab Toxicol, 2018, 14(5): 483-491. DOI: 10.1080/17425255.2018.1472236.
[15]	GANE E, LAWITZ E, PUGATCH D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment[J]. N Engl J Med, 2017, 377(15): 1448-1455. DOI: 10.1056/NEJMoa1704053.
[16]	University of Liverpool. HEP drug interactions[DB/OL]. [2020-09-30]. https://www.hep-druginteractions.org/.
[17]	HSU SJ, CHIU MC, FANG YJ, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C[J]. J Formos Med Assoc, 2019, 118(8): 1187-1192. DOI: 10.1016/j.jfma.2019.06.014.
[18]	SMOLDERS EJ, de KANTER CT, van HOEK B, et al. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment[J]. Drug Saf, 2016, 39(7): 589-611. DOI: 10.1007/s40264-016-0420-2.
[19]	CORNPROPST MT, DENNING JM, CLEMONS D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977[J]. J Hepatol, 2012, 56(Suppl 2): s433. DOI: 10.1016/S0168-8278(12) 61113-1.
[20]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C: A 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1961-1979. DOI: 10.3969/j.issn.1001-5256.2015.12.003. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1961-1979. DOI: 10.3969/j.issn.1001-5256.2015.12.003.
[21]	ABRAHAM GM, SPOONER LM. Sofosbuvir in the treatment of chronic hepatitis C: New dog, new tricks[J]. Clin Infect Dis, 2014, 59(3): 411-415. DOI: 10.1093/cid/ciu265.
[22]	Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on management of drug-drug interaction with direct-acting antiviral agents in chronic hepatitis C[J]. J Clin Hepatol, 2018, 34(9): 1855-1861. DOI: 10.3969/j.issn.1001-5256.2018.09.007. 中国肝炎防治基金会, 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎直接抗病毒药物应用中的药物相互作用管理专家共识[J]. 临床肝胆病杂志, 2018, 34(9): 1855-1861. DOI: 10.3969/j.issn.1001-5256.2018.09.007.
[23]	WEI L. Potential risk of drug-drug interactions associated with direct-acting antiviral regimens in Chinese urban patients with chronic hepatitis C[J]. Hepatol Int, 2019, 13(Suppl 1): s84. DOI: 10.1007/S12072-019-09936-5.
[24]	CHUANG WL, HU TH, BUGGISCH P, et al. Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis[J]. J Hepatol, 2019, 70(1, Suppl): e225. DOI: 10.1016/S0618-8278(19)30419-0.
[25]	BORGIA SM, DEARDEN J, YOSHIDA EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis[J]. J Hepatol, 2019, 71(4): 660-665. DOI: 10.1016/j.jhep.2019.05.028.
[26]	COX-NORTH P, HAWKINS KL, ROSSITER ST, et al. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction[J]. Hepatol Commun, 2017, 1(3): 248-255. DOI: 10.1002/hep4.1035.
[27]	BEINHARDT S, AL ZOAIRY R, FERENCI P, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting[J]. Transpl Int, 2016, 29(9): 999-1007. DOI: 10.1111/tri.12799.
[28]	SINGH A, KUMARI S, KUMAR P, et al. Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency[J]. J Viral Hepat, 2018, 25(12): 1501-1506. DOI: 10.1111/jvh.12983.
[29]	KUMAR M, NAYAK SL, GUPTA E, et al. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease[J]. Liver Int, 2018, 38(12): 2137-2148. DOI: 10.1111/liv.13863.
[30]	AGARWAL SK, BAGCHI S, YADAV RK. Hemodialysis patients treated for hepatitis C using a sofosbuvir-based regimen[J]. Kidney Int Rep, 2017, 2(5): 831-835. DOI: 10.1016/j.ekir.2017.04.003.
[31]	DESNOYER A, POSPAI D, LÊ MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C[J]. J Hepatol, 2016, 65(1): 40-47. DOI: 10.1016/j.jhep.2016.02.044.
[32]	DUMORTIER J, BAILLY F, PAGEAUX GP, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure[J]. Nephrol Dial Transplant, 2017, 32(12): 2065-2071. DOI: 10.1093/ndt/gfw348.
[33]	General Office of National Health Commission of the People's Republic of China. Notice on the issuance of hemodialysis management regimen for patients with negative conversion of hepatitis C virus (HCV-RNA) detection[EB/OL]. 2018. 国家卫生健康委员会办公厅. 关于印发丙型肝炎病毒(HCV-RNA)检测结果转阴患者血液透析管理方案的通知[EB/OL]. 2018.
[34]	BEGOVAC J, KRZNARIĆ J, BOGDANIĆ N, et al. Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir: A case report[J]. Medicine (Baltimore), 2018, 97(51): e13671. DOI: 10.1097/MD.0000000000013671.
[35]	HACHICHA M, BOTTA-FRIDLUND D. Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation[J]. Nephrol Ther, 2016, 12(7): 536-538. DOI: 10.1016/j.nephro.2016.05.010.
[36]	SURENDRA M, RAJU SB, SRIDHAR N, et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study[J]. Hemodial Int, 2018, 22(2): 217-221. DOI: 10.1111/hdi.12604.
[37]	CHOUDHARY NS, KUMAR A, BODH V, et al. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis[J]. Indian J Gastroenterol, 2017, 36(2): 113-116. DOI: 10.1007/s12664-017-0735-7.
[38]	Gilead Sciences. SOVALDI (Sofosbuvir) highlights of prescribing information[EB/OL].[2020-09-30]. https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
[39]	Gilead Sciences. EPCLUSA (Sofosbuvir and Velpatasvir) highlights of prescribing information[EB/OL].[2020-09-30]. https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf
[40]	Gilead Sciences. HARVONI (Ledipasvir and Sofosbuvir) highlights of prescribing information[EB/OL].[2020-09-30]. https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
[41]	Gilead Sciences. VOSEVI (Sofosbuvir, Velpatasvir, and Voxilaprevir) Highlights of prescribing information[EB/OL].[2020-09-30]. https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/vosevi/vosevi_pi.pdf
[42]	American Association for the Study of Liver Disease, Infection Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatits C[EB/OL].[2020-09-30]. https://www.hcvguidelines.org/.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (598) PDF downloads(45)

Application of sofosbuvir in HCV-infected patients with end-stage renal disease undergoing hemodialysis

DOI: 10.3969/j.issn.1001-5256.2021.05.045

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Application of sofosbuvir in HCV-infected patients with end-stage renal disease undergoing hemodialysis

DOI: 10.3969/j.issn.1001-5256.2021.05.045

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content